Services

The Vaccine Formulation Institute (VFI) offers formulation studies of vaccine antigens with adjuvants. VFI adjuvants include SWE, an oil-in-water emulsion available at GMP grade (Sepivac SWE™), and combination adjuvants (emulsions and liposomes with/ without QS21 saponin and/or TLR agonists). Aluminum salts and dmLT adjuvants can also be included in formulation studies. The vaccine antigen is usually provided to VFI by the applicant. Formulations are tested at the VFI for compatibility, stability and antigen integrity (conditional to the transfer of method and / or reagents to VFI) determining their suitability for in vivo use. A detailed report of the study results will be provided by VFI to the user, as well as adjuvanted formulations for use in in vivo studies. Please feel free to contact VFI before applying to the service to discuss feasibility and outline of the study.

​

The following services specifically may be included:

​

• Formulation development and characterisation. 

 

•  Upscaling of emulsion and liposome-based adjuvants from lab-scale to pilot-scale. 

 

•  Technological transfer of pilot scale process; manufacturing parameters of emulsion and liposome adjuvants and manufacturing of preclinical tox batch. 

 

•  Provision of emulsion and liposome-based adjuvants at GMP grade for use in clinical studies

​

• Provision of non-GLP emulsion and liposome-based adjuvants for in vivo studies of adjuvanted formulations in a variety of species.